

2019 Future of Devic's Syndrome R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2E8D8530161EN.html>

Date: February 2019

Pages: 80

Price: US\$ 2,199.00 (Single User License)

ID: 2E8D8530161EN

Abstracts

The global demand for Devic's Syndrome treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Devic's Syndrome pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Devic's Syndrome pipeline companies from advancing their products into Phase 3 or Phase 4.

Devic's Syndrome Report Description-

The 2019 pipeline study on Devic's Syndrome pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Devic's Syndrome pipeline compounds.

The Devic's Syndrome pipeline guide presents information on all active drugs currently being developed for Devic's Syndrome. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Devic's Syndrome pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Devic's Syndrome drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Devic's Syndrome product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Devic's Syndrome pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Devic's Syndrome pipeline report includes-

An overview of Devic's Syndrome disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Devic's Syndrome pipeline

Company wise list of Devic's Syndrome pipeline

Mechanism of Action wise Devic's Syndrome pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Devic's Syndrome pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Devic's Syndrome pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Devic's Syndrome pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL DEVIC'S SYNDROME PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Devic's Syndrome Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Devic's Syndrome pipeline, H1- 2019
- 3.5 Mechanism of Action wise Devic's Syndrome Pipeline Candidates

4 ABIDE THERAPEUTICS INC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 4.1 Abide Therapeutics Inc Business Profile
- 4.2 Abide Therapeutics Inc Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator
 - 4.3.2 Collaborator/Co-Developer
 - 4.3.3 Route of Administration
 - 4.3.4 Orphan Drug/Fast Track/Special Designation
 - 4.3.5 Geography
 - 4.3.6 Type of Molecular Entity

- 4.3.7 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 ACER THERAPEUTICS INC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 5.1 Acer Therapeutics Inc Business Profile
- 5.2 Acer Therapeutics Inc Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 ALEXION PHARMACEUTICALS INC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 6.1 Alexion Pharmaceuticals Inc Business Profile
- 6.2 Alexion Pharmaceuticals Inc Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer
 - 6.3.3 Route of Administration
 - 6.3.4 Orphan Drug/Fast Track/Special Designation
 - 6.3.5 Geography
 - 6.3.6 Type of Molecular Entity
 - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action

6.6 Clinical/Pre-clinical Trial Details

6.7 Latest Drug Developments

7 ANVIL BIOSCIENCES NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

7.1 Anvil Biosciences Business Profile

7.2 Anvil Biosciences Neuromyelitis Optica (Devic's Syndrome) Drug Details

7.3 Drug Snapshot

7.3.1 Originator

7.3.2 Collaborator/Co-Developer

7.3.3 Route of Administration

7.3.4 Orphan Drug/Fast Track/Special Designation

7.3.5 Geography

7.3.6 Type of Molecular Entity

7.3.7 Current Status

7.4 Drug Overview

7.5 Drug Mechanism of Action

7.6 Clinical/Pre-clinical Trial Details

7.7 Latest Drug Developments

8 BIOGEN INC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

8.1 Biogen Inc Business Profile

8.2 Biogen Inc Neuromyelitis Optica (Devic's Syndrome) Drug Details

8.3 Drug Snapshot

8.3.1 Originator

8.3.2 Collaborator/Co-Developer

8.3.3 Route of Administration

8.3.4 Orphan Drug/Fast Track/Special Designation

8.3.5 Geography

8.3.6 Type of Molecular Entity

8.3.7 Current Status

8.4 Drug Overview

8.5 Drug Mechanism of Action

8.6 Clinical/Pre-clinical Trial Details

8.7 Latest Drug Developments

9 BIONURE FARMA SL NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 9.1 Bionure Farma SL Business Profile
- 9.2 Bionure Farma SL Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 9.3 Drug Snapshot
 - 9.3.1 Originator
 - 9.3.2 Collaborator/Co-Developer
 - 9.3.3 Route of Administration
 - 9.3.4 Orphan Drug/Fast Track/Special Designation
 - 9.3.5 Geography
 - 9.3.6 Type of Molecular Entity
 - 9.3.7 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10 CHORD THERAPEUTICS SARL NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 10.1 Chord Therapeutics Sarl Business Profile
- 10.2 Chord Therapeutics Sarl Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 10.3 Drug Snapshot
 - 10.3.1 Originator
 - 10.3.2 Collaborator/Co-Developer
 - 10.3.3 Route of Administration
 - 10.3.4 Orphan Drug/Fast Track/Special Designation
 - 10.3.5 Geography
 - 10.3.6 Type of Molecular Entity
 - 10.3.7 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11 CHUGAI PHARMACEUTICAL CO LTD NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 11.1 Chugai Pharmaceutical Co Ltd Business Profile
- 11.2 Chugai Pharmaceutical Co Ltd Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 11.3 Drug Snapshot
 - 11.3.1 Originator
 - 11.3.2 Collaborator/Co-Developer
 - 11.3.3 Route of Administration
 - 11.3.4 Orphan Drug/Fast Track/Special Designation
 - 11.3.5 Geography
 - 11.3.6 Type of Molecular Entity
 - 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 CLENE NANOMEDICINE INC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 12.1 Clene Nanomedicine Inc Business Profile
- 12.2 Clene Nanomedicine Inc Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography
 - 12.3.6 Type of Molecular Entity
 - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13 ENDECE LLC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 13.1 Endece LLC Business Profile
- 13.2 Endece LLC Neuromyelitis Optica (Devic's Syndrome) Drug Details

- 13.3 Drug Snapshot
 - 13.3.1 Originator
 - 13.3.2 Collaborator/Co-Developer
 - 13.3.3 Route of Administration
 - 13.3.4 Orphan Drug/Fast Track/Special Designation
 - 13.3.5 Geography
 - 13.3.6 Type of Molecular Entity
 - 13.3.7 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details
- 13.7 Latest Drug Developments

14 ENHANX BIOPHARM INC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 14.1 EnhanX Biopharm Inc Business Profile
- 14.2 EnhanX Biopharm Inc Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 14.3 Drug Snapshot
 - 14.3.1 Originator
 - 14.3.2 Collaborator/Co-Developer
 - 14.3.3 Route of Administration
 - 14.3.4 Orphan Drug/Fast Track/Special Designation
 - 14.3.5 Geography
 - 14.3.6 Type of Molecular Entity
 - 14.3.7 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

15 FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 15.1 Fundacio Clinic per a la Recerca Biomedica Business Profile
- 15.2 Fundacio Clinic per a la Recerca Biomedica Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 15.3 Drug Snapshot
 - 15.3.1 Originator

- 15.3.2 Collaborator/Co-Developer
- 15.3.3 Route of Administration
- 15.3.4 Orphan Drug/Fast Track/Special Designation
- 15.3.5 Geography
- 15.3.6 Type of Molecular Entity
- 15.3.7 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

16 HANALL BIOPHARMA CO LTD NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 16.1 HanAll Biopharma Co Ltd Business Profile
- 16.2 HanAll Biopharma Co Ltd Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 16.3 Drug Snapshot
 - 16.3.1 Originator
 - 16.3.2 Collaborator/Co-Developer
 - 16.3.3 Route of Administration
 - 16.3.4 Orphan Drug/Fast Track/Special Designation
 - 16.3.5 Geography
 - 16.3.6 Type of Molecular Entity
 - 16.3.7 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17 IMSTEM BIOTECHNOLOGY INC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 17.1 Imstem Biotechnology Inc Business Profile
- 17.2 Imstem Biotechnology Inc Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 17.3 Drug Snapshot
 - 17.3.1 Originator
 - 17.3.2 Collaborator/Co-Developer
 - 17.3.3 Route of Administration
 - 17.3.4 Orphan Drug/Fast Track/Special Designation

- 17.3.5 Geography
- 17.3.6 Type of Molecular Entity
- 17.3.7 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18 LFB SA NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 18.1 LFB SA Business Profile
- 18.2 LFB SA Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 18.3 Drug Snapshot
 - 18.3.1 Originator
 - 18.3.2 Collaborator/Co-Developer
 - 18.3.3 Route of Administration
 - 18.3.4 Orphan Drug/Fast Track/Special Designation
 - 18.3.5 Geography
 - 18.3.6 Type of Molecular Entity
 - 18.3.7 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19 NIHON PHARMACEUTICALS CO LTD NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 19.1 Nihon Pharmaceuticals Co Ltd Business Profile
- 19.2 Nihon Pharmaceuticals Co Ltd Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 19.3 Drug Snapshot
 - 19.3.1 Originator
 - 19.3.2 Collaborator/Co-Developer
 - 19.3.3 Route of Administration
 - 19.3.4 Orphan Drug/Fast Track/Special Designation
 - 19.3.5 Geography
 - 19.3.6 Type of Molecular Entity
 - 19.3.7 Current Status

- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20 ORION BIOSCIENCE INC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 20.1 Orion BioScience Inc Business Profile
- 20.2 Orion BioScience Inc Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 20.3 Drug Snapshot
 - 20.3.1 Originator
 - 20.3.2 Collaborator/Co-Developer
 - 20.3.3 Route of Administration
 - 20.3.4 Orphan Drug/Fast Track/Special Designation
 - 20.3.5 Geography
 - 20.3.6 Type of Molecular Entity
 - 20.3.7 Current Status
- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

21 TOLERION INC NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

- 21.1 Tolerion Inc Business Profile
- 21.2 Tolerion Inc Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 21.3 Drug Snapshot
 - 21.3.1 Originator
 - 21.3.2 Collaborator/Co-Developer
 - 21.3.3 Route of Administration
 - 21.3.4 Orphan Drug/Fast Track/Special Designation
 - 21.3.5 Geography
 - 21.3.6 Type of Molecular Entity
 - 21.3.7 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details

21.7 Latest Drug Developments

22 VICORE PHARMA AB NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

22.1 Vicore Pharma AB Business Profile

22.2 Vicore Pharma AB Neuromyelitis Optica (Devic's Syndrome) Drug Details

22.3 Drug Snapshot

22.3.1 Originator

22.3.2 Collaborator/Co-Developer

22.3.3 Route of Administration

22.3.4 Orphan Drug/Fast Track/Special Designation

22.3.5 Geography

22.3.6 Type of Molecular Entity

22.3.7 Current Status

22.4 Drug Overview

22.5 Drug Mechanism of Action

22.6 Clinical/Pre-clinical Trial Details

22.7 Latest Drug Developments

23 VIELA BIO NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE DETAILS

23.1 Viela Bio Business Profile

23.2 Viela Bio Neuromyelitis Optica (Devic's Syndrome) Drug Details

23.3 Drug Snapshot

23.3.1 Originator

23.3.2 Collaborator/Co-Developer

23.3.3 Route of Administration

23.3.4 Orphan Drug/Fast Track/Special Designation

23.3.5 Geography

23.3.6 Type of Molecular Entity

23.3.7 Current Status

23.4 Drug Overview

23.5 Drug Mechanism of Action

23.6 Clinical/Pre-clinical Trial Details

23.7 Latest Drug Developments

24 YANTAI RONGCHANG PHARMACEUTICAL CO.,LTD. NEUROMYELITIS OPTICA

(DEVIC'S SYNDROME) PIPELINE DETAILS

- 24.1 Yantai Rongchang Pharmaceutical Co.,Ltd. Business Profile
- 24.2 Yantai Rongchang Pharmaceutical Co.,Ltd. Neuromyelitis Optica (Devic's Syndrome) Drug Details
- 24.3 Drug Snapshot
 - 24.3.1 Originator
 - 24.3.2 Collaborator/Co-Developer
 - 24.3.3 Route of Administration
 - 24.3.4 Orphan Drug/Fast Track/Special Designation
 - 24.3.5 Geography
 - 24.3.6 Type of Molecular Entity
 - 24.3.7 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

25. LATEST DEVIC'S SYNDROME DRUG PIPELINE DEVELOPMENTS, 2019

26. APPENDIX

- 26.1 About Us
- 26.2 Sources and Methodology
- 26.3 Contact Information

I would like to order

Product name: 2019 Future of Devic's Syndrome R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2E8D8530161EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2E8D8530161EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

